Toripalimab |
Catalog No.GC64561 |
토리팔리맙은 중국 최초의 국내 항종양 PD-1 항체다. 토리팔리맙은 PD-1에 대한 선택적 재조합 인간화 단일클론항체이다. 토리팔리맙은 PD-1에 결합하여 리간드와의 상호작용을 차단할 수 있습니다. 토리팔리맙은 흑색종, 폐암, 소화관 종양, 간담도 및 췌장 종양, 신경내분비 종양, 비인두암 및 요로상피암과 같은 종양에서 1차 항종양 효과를 나타냈습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1924598-82-2
Sample solution is provided at 25 µL, 10mM.
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma[1].
[1]. Lin Zhang, et al. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *